{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "When federal drug officials suspected in 1992 that a popular allergy pill might cause heart problems, they turned to their own scientists. Their trial confirmed the danger, and the drug was pulled from the market. Eight years later, similar worries surrounded the arthritis pill Vioxx. But by then, the Food and Drug Administration had shifted gears, slashing its laboratories and network of independent drug safety experts in favor of hiring more people to approve drugs, changes that arose under an unusual agreement that has left the agency increasingly reliant on and bound by drug company money. Discovering Vioxx's dangers would take four more years.", "headline": {"main": "REGULATION REDEFINED: The F.D.A. Shifts Focus; At F.D.A., Strong Drug Ties and Less Monitoring", "kicker": "Regulation Redefined"}, "abstract": "Food and Drug Administration made arrangement with drug companies in 1992 that has increased agency's dependence on corporate money to finance much of its drug testing efforts, special report, Regulation Redefined: The FDA Shifts Focus; critics say this has caused delay in discovering dangers of certain drugs, including Vioxx; members of Congress, internal FDA whistleblower and prominent medical journals say agency is incapable of uncovering perils of drugs that have been approved and are in nationwide distribution; some accuse it of being cozy with drug makers; under 1992 agreement, forced by White House and Congress, drug industry promised to give FDA millions, but only if agency spent specified level of money on new drug approvals; result is that in past 11 years, spending on reviews has increased to more than four-fifths of budget of agency's drug center, from about half, and there has been drastic cut in studies to ensure safety of drugs already on the market; FDA has never been able to require drug makers to undertake new safety tests once drug is approved; agency now relies almost entirely on willingness of drug makers to report problems that crop up after drug has been approved to ensure safety of nation's drug supply; critics say this dependency has diminished agency's willingness to confront drug makers, making it timid and leaving patients vulnerable; photos; graphs (L)", "print_page": "1", "word_count": 3496, "_id": "4fd241498eb7c8105d7d961c", "snippet": "Critics say the F.D.A.'s efforts to monitor the ill effects of drugs that are on the market are a shadow of what they should be.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/06/health/06fda.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "ACCIDENTS AND SAFETY"}, {"name": "subject", "value": "WHISTLE-BLOWERS"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS; John Schwartz contributed reporting for this article"}, "document_type": "article", "pub_date": "2004-12-06T00:00:00Z", "section_name": "Front Page; Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "A few months ago, as I trudged down the stairs of my office building, deep in my thoughts, I noticed a dark-haired woman waving to me from the window of her car. She looked vaguely familiar, but I couldn't place her. Like quite a few others, she had slipped out of my mental Rolodex. In my brain, the synaptic traces that connected us had frayed. Yet again, I had misplaced an entire human being. ''So wonderful to see you,'' she said, inquiring by name after every member of my family, including the two dogs. Apparently she was not a casual acquaintance. Fending off panic, I proceeded through a mental list: Work? School? Synagogue? I couldn't visualize her in these places. I was about to cut and run with a quick ''nice to see you, too'' when the rear window slid down, revealing a toothy grin.", "headline": {"main": "In Search of Lost Time"}, "abstract": "Cathryn Jakobson Ramin article on concern about her memory decline in middle age and search for reasons; explains neurological changes in adult brain and doctors' conclusion that her own problems stem from mild traumatic brain injuries, some dating to childhood mishaps; describes positive effects of taking Adderall, which, with Ritalin, appears to provide boost in focus, although with some unwelcome side effects (M)", "print_page": "76", "word_count": 5401, "_id": "4fd241498eb7c8105d7d95a2", "snippet": "Was it the fog of a late-40's brain or something more serious? The author's scientific journey in pursuit of her memory.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/05/magazine/05MEMORY.html", "multimedia": [{"url": "images/2004/12/02/magazine/05memo.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/12/02/magazine/05memo.75.jpg"}, "type": "image", "height": 75}, {"subtype": "tiny_thumb", "legacy": {"tinythumbwidth": 55, "tinythumbheight": 55, "hastinythumb": "Y"}, "type": "image", "width": 55, "height": 55}], "subsection_name": null, "keywords": [{"name": "subject", "value": "AGE, CHRONOLOGICAL"}, {"name": "subject", "value": "MEMORY"}, {"name": "subject", "value": "BRAIN"}, {"name": "subject", "value": "ADDERALL (DRUG)"}, {"name": "subject", "value": "RITALIN (DRUG)"}], "byline": {"person": [{"firstname": "Cathryn", "middlename": "Jakobson", "lastname": "Ramin", "rank": 1, "role": "reported", "organization": ""}], "original": "By Cathryn Jakobson Ramin"}, "document_type": "article", "pub_date": "2004-12-05T00:00:00Z", "section_name": "Health; Magazine"}, {"type_of_material": "News", "blog": [], "news_desk": "Style Desk", "lead_paragraph": "TO millions of Americans, Botox is a magic bullet. A few pinpricks and in a day the face is returned to an approximation of its teenage self, unlined and uninjured by the relentless insult of adult life. But devotees of the youth potion were dismayed last week to learn that four people who went for wrinkle-smoothing treatments had been hospitalized for possible botulism poisoning.", "headline": {"main": "Is It Botox, or Is It Bogus?"}, "abstract": "Botulism poisoning cases have led die-hard fans of Botox injections to question drug's efficacy and inherent dangers; Centers for Disease Control and Prevention are investigating four cases of possible poisonings; photos (M)", "print_page": "1", "word_count": 1709, "_id": "4fd280958eb7c8105d84bc95", "snippet": "Four cases of possible botulism poisoning raise concerns about the market for do-it-yourself anti-aging compounds.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/05/fashion/05BOTU.html", "multimedia": [{"url": "images/2004/12/05/fashion/05botu.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/12/05/fashion/05botu.75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "organizations", "value": "CENTERS FOR DISEASE CONTROL AND PREVENTION"}, {"name": "subject", "value": "POISONING AND POISONS"}, {"name": "subject", "value": "BOTOX (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SKIN"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "BOTULISM"}, {"name": "subject", "value": "COSMETICS AND TOILETRIES"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Alex", "rank": 1, "lastname": "KUCZYNSKI"}], "original": "By ALEX KUCZYNSKI"}, "document_type": "article", "pub_date": "2004-12-05T00:00:00Z", "section_name": "Health; Style"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "To people who have struggled for a lifetime to lose weight, the new drug called rimonabant sounds like a dream come true. It will make a person uninterested in fattening foods, they have heard from news reports and word of mouth. Weight will just melt away, and fat accumulating around the waist and abdomen will be the first to go. And by the way, those who take it will end up with higher levels of H.D.L., the good cholesterol. If they smoke, they will find it easier to quit. If they are heavy drinkers, they will no longer crave alcohol.", "headline": {"main": "Will a New Drug Melt the Pounds? It May, but Doctors Urge Caution"}, "abstract": "Medical researchers caution overweight people who are already pinning hope of losing weight on new drug called rimonabant, which has not yet been approved for sale in United States or anywhere else; note lack of any published studies from clinical trials to justify any of claims for what some patients are already calling a miracle drug; its maker, Sanofi-Aventis, has not yet submitted its application for marketing to Food and Drug Administration; description of how rimonabant works; photos (M)", "print_page": "1", "word_count": 1449, "_id": "4fd280958eb7c8105d84bca8", "snippet": "While rimonabant sounds like a dream come true to people who are trying to lose weight, some researchers say the drug may be getting more attention than it deserves.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/05/health/05miracle.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "SANOFI-AVENTIS"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DIET AND NUTRITION"}, {"name": "subject", "value": "WEIGHT"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "OBESITY"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RIMONABANT (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2004-12-05T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Sports Desk", "lead_paragraph": "IF there is a shred of accountability in Jason Giambi, he will not hide behind lawyers and his no-longer-secret federal grand jury testimony. If his goal is to regain a modicum of credibility as a man of major league character, he will soon stand up and proclaim himself a classic cautionary tale on the scourge of sports pharmacology, because that is exactly what he appears to be. Giambi is no disgraced track star or cyclist caught red-blooded with the hard evidence coursing through his capillaries. He is no disposable Olympic hero, no withered wrestler, no retired football player limping through old age. He is no Ken Caminiti, the former National League most valuable player and admitted steroid user, killing himself, according to last month's medical examiner's report, with recreational drugs.", "headline": {"main": "Time for Giambi to Show Strength, Without Any Chemicals", "kicker": "Sports of The Times"}, "abstract": null, "print_page": "1", "word_count": 999, "_id": "4fd241498eb7c8105d7d955a", "snippet": "If there is a shred of accountability in Jason Giambi, he will not hide behind lawyers and his no-longer-secret grand jury testimony.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/03/sports/baseball/03araton.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GIAMBI, JASON"}, {"name": "organizations", "value": "DRUG ENFORCEMENT ADMINISTRATION"}, {"name": "organizations", "value": "BAY AREA LABORATORY CO-OPERATIVE"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Harvey", "rank": 1, "lastname": "ARATON"}], "original": "By HARVEY ARATON"}, "document_type": "article", "pub_date": "2004-12-03T00:00:00Z", "section_name": "Sports"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The growth in health care spending by private employers slowed in recent years, creating some optimism that the employers had turned the corner in their struggle with rising costs. But any relief appears to have been short lived, according to a study to be released today. Growth in spending in the first half of 2004 was about the same as it was in 2003, according to the Center for Studying Health System Change, a nonprofit research group in Washington that tracks spending levels. Largely driven by the growth in hospital costs, total health care spending increased 7.5 percent.", "headline": {"main": "No Relief Seen In the Growth Of Employers' Health Costs"}, "abstract": null, "print_page": "4", "word_count": 787, "_id": "4fd244348eb7c8105d7ddd4f", "snippet": "The growth in health care spending by private employers slowed in recent years, creating some optimism that the employers had turned the corner in their struggle with rising costs. But any relief appears to have been short lived, according to a study...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/02/business/02hospital.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "INSURANCE"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Reed", "rank": 1, "lastname": "ABELSON"}], "original": "By REED ABELSON"}, "document_type": "article", "pub_date": "2004-12-02T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Abortion opponents have long considered the Senate to be a daunting roadblock for new abortion restrictions and conservative judicial nominees, halting many of the initiatives of a sympathetic House and a president committed to ''a culture of life.'' But now, both sides in the abortion struggle agree, the Senate is changing. As a result of November's election, the next Senate will have a bigger, more conservative Republican majority and several new opponents of abortion -- including some of the most intense abortion foes in politics, like Tom Coburn, a doctor and newly elected senator from Oklahoma, who campaigned as ''a committed defender of the sanctity of life in all of its stages.''", "headline": {"main": "Changing Senate Looks Much Better to Abortion Foes", "kicker": "Political Memo"}, "abstract": "New Senate will have bigger, more conservative Republican majority and several new opponents of abortion, including Tom Coburn, one of most intense abortion foes in country; anti-abortion leaders say several restrictions previously introduced have better chance for full consideration and passage, and that political tide is gradually turning their way; say restrictions have broad support from American public and are long overdue, such as requirement that women seeking abortions after 20 weeks be offered pain-relieving medication for fetus; Sen Barbara Boxer says ultimate goal of anti-abortion movement is to repeal Roe v Wade and women's right to choose; photo (M)", "print_page": "34", "word_count": 1326, "_id": "4fd241488eb7c8105d7d950c", "snippet": "The next Senate will have a bigger, more conservative Republican majority and several new opponents of abortion.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/02/politics/02abortion.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BOXER, BARBARA"}, {"name": "persons", "value": "COBURN, TOM"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "subject", "value": "ABORTION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ROE V WADE (SUPREME COURT DECISION)"}, {"name": "subject", "value": "LAW AND LEGISLATION"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Robin", "rank": 1, "lastname": "TONER"}], "original": "By ROBIN TONER"}, "document_type": "article", "pub_date": "2004-12-02T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The main pension fund of New York State filed a federal lawsuit yesterday against Merck & Company, accusing it of misleading shareholders about the safety of its arthritis pain drug Vioxx, which has since been withdrawn. The suit, brought in United States District Court in Trenton, said that the pension fund lost about $171 million on Sept. 30, when the company, citing increased heart risks in tests of people who had used Vioxx for more than 18 months, withdrew it from the market. On that day, the price of a share of Merck stock plummeted 27 percent, and it has since drifted lower. Merck shares are down almost 40 percent so far this year, though they closed up 35 cents yesterday, at $28.02.", "headline": {"main": "New York's Pension Fund Files Own Suit Against Merck"}, "abstract": "New York State Common Retirement Fund files lawsuit against Merck & Co, accusing it of misleading shareholders about safety of its arthritis pain drug Vioxx, which has since been withdrawn; suit says pension fund lost about $171 million in Sept 30, when company withdrew drug from market; New York State Comptroller Alan G Hevesi, who is also pension fund's trustee, says Merck knew but failed to disclose that growing evidence indicated that Vioxx users were at increased risk of heart attacks, strokes and death; suit also names several individuals, including Merck's chief executive Raymond V Gilmartin (M)", "print_page": "1", "word_count": 599, "_id": "4fd280938eb7c8105d84bbae", "snippet": "The main pension fund of New York State filed a lawsuit against Merck & Company, accusing it of misleading shareholders about the safety of its pain drug Vioxx.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/12/01/business/01merck.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "HEVESI, ALAN G"}, {"name": "persons", "value": "GILMARTIN, RAYMOND V"}, {"name": "glocations", "value": "NEW YORK STATE"}, {"name": "organizations", "value": "NEW YORK STATE COMMON RETIREMENT FUND"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "PENSIONS AND RETIREMENT PLANS"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Barry", "rank": 1, "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2004-12-01T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 8, "offset": 0, "time": 55}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}